Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Activaero’s AKITA JET receives FDA 510(K) clearance

Dublin, Ohio, December 9, 2009 – Activaero, the world leader in the design of controlled breathing drug delivery technologies that maximize the efficiency and precision of inhaled drugs, today announced that the US Food and Drug Administration (FDA) has issued 510(K) Clearance for the Company’s AKITA® JET inhalation system. The 510(k) clearance, while for general purpose use, helps to pave the way for Activaero to utilize the AKITA® JET device in clinical trials to develop combination products in the United States. In 2007, Activaero received the 510(k) clearance for the AKITA² APIXNEB inhalation device, which is currently in clinical trials for a variety of new therapies.

William Zimlich, CEO of Activaero America, Inc. commented: “We are pleased to add this revolutionary controlled breathing device to our product offering for the US market. By receiving 510(K) Clearance for the AKITA® JET, we are now well on our way toward enhancing our global strategy of developing best-in-class pulmonary drug delivery devices.”

Clinical studies have demonstrated that Activaero’s AKITA technology increases deposition efficiency of inhalation therapy by controlled breathing. Aerosolized drug is delivered at distinct intervals within the inspiratory cycle to enhance inhaled treatments in patients where the treatment safety and efficacy profile may be improved by drug targeting. The system uses a SmartCard technology that ensures the treatment regimen can be specifically tailored to a patient’s respiratory condition and drug dosing needs.

About Activaero GmbH

Activaero is the world leader in the design of controlled breathing drug delivery technologies that maximize the efficiency and precision of inhaled drugs. These innovative technologies enable safer, more cost-efficient, and effective options for inhaled treatments of respiratory diseases. As a center of excellence in aerosol medicine, Activaero has a track record in supporting its partners in pre-clinical and clinical projects for pulmonary drug development. In addition to AKITA technologies, Activaero markets Watchhaler™, a revolutionary children’s spacer that controls the patient’s inhaled volume and flow-rate. Activaero GmbH is located in Gemuenden/Wohra and Munich (Germany) and Dublin, Ohio (USA). Further information on Activaero can be found at

Further Information:

Activaero America, Inc.

William C. Zimlich

P.O. Box 351

Dublin, OH 43017-9684, USA

Phone: +1 614 761 3555

Fax: +1 614 761 3505


Dr. Douglas Pretsell

Account Director, Munich Bureau Chief

College Hill

Phone: +49 (0)89 57 00 18 06


Publisher Contact Information:

+1 614 761 3555

Company profile of Activaero (acquired by Vectura)
Past press releases of Activaero (acquired by Vectura).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.